ESR1 and breast carcinoma: The clinical course and prognosis of triple-negative patients, which are seen in 10% to 20% of breast cancers, are quite poor.[7] ER and HER2 positivity are seen in 70% to 75% and 15% to 20%, respectively, in breast cancers.